Key clinical trials of nadofaragene firadenovec
| Drug(s) | Indication | Phase | Status | Location | Identifier | Sponsor |
|---|---|---|---|---|---|---|
| Nadofaragene firadenovec | Bladder cancer | III | Active, not recruiting | USA | NCT02773849, rAd-IFN-CS003 | Ferring Pharmaceuticals |
| Nadofaragene firadenovec | Bladder cancer | II | Completed | USA | NCT01687244, rAd-IFN-CS002 | FKD Therapies Oy |
| Nadofaragene firadenovec | Bladder cancer | Ib | Completed | USA | NCT01162785 | M.D. Anderson Cancer Center |
| Nadofaragene firadenovec | Bladder cancer | I | Completed | USA | NCT00536588 | Merck Sharp & Dohme LLC |
| Nadofaragene firadenovec, celecoxib, gemcitabine | Mesothelioma | III | Active, not recruiting | Global | INFINITE, NCT03710876, EudraCT2017-003169-82, rAd-IFN-MM301 | Trizell Ltd. |
| Nadofaragene firadenovec, celecoxib, chemotherapy | Mesothelioma | Ia | Completed | USA | NCT01119664 | Abramson Cancer Center of the University of Pennsylvania |
| Nadofaragene firadenovec | Mesothelioma | I | Completed | USA | NCT01212367 | Abramson Cancer Center of the University of Pennsylvania |
aAlso reported as a phase II trial